|
|
Article: Genzyme reports DCOR trial using Renagel in dialysis patients results in lower death rates.
- Article from:
- Transplant News
- Article date:
- August 15, 2005
CopyrightCOPYRIGHT 2005 Transplant Communications, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Genzyme Corporation, Cambridge, MA, announced the company has achieved positive results from the Dialysis Clinical Outcomes Revisited (DCOR) trial, the largest outcomes study ever conducted in the hemodialysis population. The three- year trial involving more than 2,100 patients compared the difference in mortality and morbidity outcomes for patients receiving Renagel (sevelamer hydrochloride) with those using calcium-based phosphate binders. Renagel is a polymer that binds excess phosphorous in the blood.
The study found that Renagel use resulted in the strongest clinical benefit in two groups of patients: those who were treated for two years or more, and those ...